News for OncoCyte Corporation (OCX)

Key Highlights: OncoCyte Corporation (OCX) targets FDA approval for its clinical assay by mid-2026. Analysts forecast a potential 60.14% upside in the stock

OncoCyte Corporation (NASDAQ:OCX) Q1 2025 Earnings Conference Call May 12, 2025 5:00 PM ETCompany ParticipantsGabby Woody - Executive Assistant, HR...

Oncocyte (OCX) secures Central IRB approval and partners with top U.S. transplant centers for its organ transplant rejection monitoring test kit trial.

Oncocyte's (OCX) blood-based transplant rejection assay demonstrates long-term clinical validity in patients up to 13.7 years post-transplant. Study val

STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICLâ„¢) for vision correction

New York-based Marblegate Acquisition Corp. (GATE) is up over 55 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.

OncoCyte Corporation (NASDAQ:OCX) Q4 2024 Earnings Conference Call March 24, 2025 5:00 PM ETCompany ParticipantsGabby Woody - Executive Assistant, HR...

Q4 2024 revenue of $1.5 million in pharma services; full year revenue of $1.9 millionGraftAssure RUO assay launched July 2024Signed strategic partner and invest

The following slide deck was published by OncoCyte Corporation in conjunction with their 2024 Q4 earnings call.

IRVINE, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. ( OCX), a pioneering diagnostics technology company, today announced that it will report fou

Will there be a recession? How will new tariffs impact the U.S.

We recently published a list of 12 Penny Stocks with Insider Buying in 2025.

Insider trading can be a reliable signal for gauging the degree of confidence that management has in the future of their company.

We recently published a list of 10 Cheapest Stocks Insiders Are Buying Recently.

Why should we be interested in affordable stocks? Some investors like to look for cheaper stocks in order to diversify their portfolios, because these penny stocks often operate in different industries...

OncoCyte stock hits 52-week low at $1.92 amid market challenges

**media[509413,509414]**

Medicare coverage expanded following study showing that monitoring with Oncocyte's assay significantly reduces time to rejection diagnosis in patients with newl

**media[487610]**